Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.

AIRT reports higher first-quarter fiscal 2026 revenue, driven by strong Ground Support Equipment gains despite a deeper loss.

FRD delivers robust first-quarter fiscal 2026 results with rising sales, stronger margins and a sharp swing to profitability in key segments.

FRD delivers robust first-quarter fiscal 2026 results with rising sales, stronger margins and a sharp swing to profitability in key segments.

NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.

SENEA reports higher first-quarter fiscal 2026 earnings, driven by improved pricing and mix, despite lower sales and co-pack volume issues.

SENEA reports higher first-quarter fiscal 2026 earnings, driven by improved pricing and mix, despite lower sales and co-pack volume issues.

Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.

Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.

Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.